Novo Nordisk /
Omeros
Novo Nordisk takes over Omeros’ zaltenibart program
Source for the buyer and target: Omeros Corporation
For the buyer and target.
“Under the Agreement, Omeros sold and transferred, and Novo Nordisk purchased and assumed, certain assets and liabilities related to the Compounds and Products, and the parties granted and received certain intellectual property licenses to facilitate the continued development and commercialization activities of both companies (the “Transaction”).”
Published 1 Dec 2025
Open the sourceWhat happened
Novo Nordisk completed a transaction with Omeros covering global rights to develop and commercialize zaltenibart and related assets. Omeros received $240.0 million upfront, with additional development, approval and sales-based milestone payments possible. [01]
Omeros is eligible for milestone payments tied to the program and royalties on net sales of commercialized products. [01]
The source
Everything on this page comes from the source below, quoted word for word.
Novo Nordisk takes over Omeros’ zaltenibart program
This document is the source for the companies, stage, figure and people on this page.
Open the sourceTimeline
Every date the source states, in order, each with the words it comes from. Anything marked ahead is a target the source gives, not something that has happened.
The same firms, in other deals
The firms' deal history and connections across other deals.
These firms' full profiles are part of Pro.
Get ProAlready a member? Sign in
Pro is open to everyone.
By email · Weekly